Arcturus Therapeutics Holdings is a global clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Co.'s coronavirus disease 2019 vaccine candidate, ARCT-021, is designed to promote immune responses to the spike protein of the Severe Acute Respiratory Syndrome-2 virus, which is the part of the virus that allows infection to occur. The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC levels. The ARCT stock yearly return is shown above.
The yearly return on the ARCT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARCT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|